Wikidata

(Q113893926)

English

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

clinical trial

In more languages

Statements

short name
MANIFEST-2 (English)
0 references
title
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (English)
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Canada
0 references
France
0 references
Hungary
0 references
Italy
0 references
Netherlands
0 references
Poland
0 references
Spain
0 references
Taiwan
0 references
United Kingdom
0 references
start time
19 November 2020
0 references
end time
March 2024
0 references
number of participants
400
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q113893926&oldid=2148707498"